Study-Drug Administration and Follow-up Five sufferers didn’t receive any dosages of the analysis drug and were not included in the safety evaluation. The study medication was discontinued for reasons other than death in 368 patients in the darbepoetin alfa group and 412 patients in the placebo group . The analysis was terminated on September 1, 2012, with a median follow-up of 28 weeks. Vital status at study termination was unknown for 13 patients in the darbepoetin alfa group and 21 in the placebo group because of loss to follow-up or withdrawal of consent .The only fertility advice/choices directed at a select handful of these women was concerning egg or embryo freezing as a opportunity for future conception. To find out which females received this limited suggestions and weren’t discriminated against for age, race or social position, Mitchell Rosen, MD of University of California, San Francisco , led a united group that surveyed over 1,000 women between the ages of 18 and 40 years who were identified as having either leukemia, Hodgkin’s, breast cancer or gastrointestinal cancer. The women had been randomly sampled from 1993 until 2007.